New Market Research Report: Alzheimer's Disease - Pipeline Review, H1 2014
Fast Market Research recommends "Alzheimer's Disease - Pipeline Review, H1 2014" from Global Markets Direct, now available
Boston, MA -- (SBWire) -- 04/15/2014 --Global Markets Direct's, 'Alzheimer's Disease - Pipeline Review, H1 2014', provides an overview of the Alzheimer's Disease's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
View Full Report Details and Table of Contents
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Alzheimer's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
Companies Mentioned in this Report: Bristol-Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Biogen Idec Inc., OXIS International, Inc., Shionogi & Co., Ltd., NsGene A/S, Amgen Inc., Sanofi, AstraZeneca PLC, Eli Lilly and Company, Perrigo Company, GlaxoSmithKline plc, Genentech, Inc., MedImmune, LLC, Merck & Co., Inc., United Biomedical, Inc., Dainippon Sumitomo Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Euroscreen S.A., Applied NeuroSolutions, Inc., Sangamo BioSciences, Inc., Grifols, S.A., NeuroDerm Ltd., Plexxikon Inc., Biotherapix SLU, Avineuro Pharmaceuticals, Inc., Panacea Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novartis AG, Aphios Corporation, Alzhyme Ltd., EnVivo Pharmaceuticals, Astellas Pharma Inc., Daewoong Pharmaceutical Co., Ltd., Eisai Co., Ltd., H. Lundbeck A/S, Jeil Pharmaceutical Co., Ltd., Les Laboratoires Servier SAS, Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Orion Oyj, Pain Therapeutics, Inc., Pfizer Inc., SK Chemicals Co., Ltd., Teva Pharmaceutical Industries Limited, Toyama Chemical Co., Ltd., Vivus, Inc., Hadasit Medical Research Services & Development Ltd, Addex Therapeutics, Evotec AG, Anavex Life Sciences Corp., Neuralstem, Inc., Genfit SA, Avanir Pharmaceuticals, Inc., Lupin Limited, Bionomics Limited, ReGenX Biosciences, LLC, Nymox Pharmaceutical Corporation, Paladin Labs Inc., Critical Outcome Technologies Inc., Acadia Pharmaceuticals Inc., Oligomerix, inc., ProteoTech, Inc., Prana Biotechnology Limited, Xenetic Biosciences plc, Biotie Therapies Corp., Neurim Pharmaceuticals Ltd, Theravance, Inc., Resverlogix Corp., Suven Life Sciences Ltd., Summit Corporation plc, CrystalGenomics, Inc., Mithridion, Inc., Teikoku Pharma USA, Inc., tesa Labtec GmbH, Eisai Ltd., Oryzon Genomics S.A., Spectrum Pharmaceuticals, Inc., TauRx Therapeutics Ltd, CoMentis, Inc., AC Immune SA, Humanetics Corporation, Accera, Inc., Sonexa Therapeutics, Inc., D-Pharm Ltd., StemCells, Inc., Proteome Sciences Plc, Upsher-Smith Laboratories, Inc., Probiodrug AG, Snowdon Inc., Domain Therapeutics SA, reMYND, AdAlta Pty Ltd., Acumen Pharmaceuticals, Inc., Neuroprofile GmbH, Wellstat Therapeutics Corporation, Celon Pharma Sp. z o.o., ALSP, Inc., IMMD Inc., CoLucid Pharmaceuticals, Inc., Metabolic Solutions Development Co., Cognition Therapeutics, Inc., BioArctic Neuroscience AB, Vaxin, Inc., Affichem, QR Pharma, Inc., NeuroNascent, Inc., Siena Biotech S.p.A., Virobay Inc., KineMed, Inc., ManRos Therapeutics, Intellect Neurosciences, Inc., TransTech Pharma, Inc., Synthetic Biologics, Inc., Intra-Cellular Therapies, Inc., Stemedica Cell Technologies, Inc., Targacept, Inc., Cortica Neurosciences, Inc., AB Science, Vitae Pharmaceuticals, Inc., Tautatis Incorporated, Lipopharma Therapeutics SL, Medisyn Technologies, Inc., PALUMED S.A., Proteostasis Therapeutics, Inc., Medestea Research & Production S.p.A., M's Science Corporation, NasVax Ltd., BrainCells Inc., Stelic Institute & Co., biOasis Technologies Inc., Pharnext SAS, PharmatrophiX, Inc., Treventis Corporation, Phenomenome Discoveries, Inc., Satori Pharmaceuticals Inc., Heptares Therapeutics Ltd., Signum Biosciences, Inc., ArmaGen Technologies, Inc., CHA Bio & Diostech Co., Ltd., B&C Biopharm, Axon Neuroscience SE, RNL BIO Co., Ltd., Clera Inc., PhysioGenix, Inc., BioChromix Pharma AB, NAL Pharmaceuticals Ltd., Laila Pharmaceuticals Pvt. Ltd., Serometrix, LLC, Archer Pharmaceuticals, Inc., Varinel, Inc., Cognosci, Inc., Reviva Pharmaceuticals Inc., Artery Therapeutics, Inc., iPierian, Inc, Naurex, Inc., SignPath Pharma Inc, PharmaNeuroBoost NV, Axerion Therapeutics, Inc., Crossbeta Biosciences B.V., Neuron Biopharma SA, Galantos Pharma GmbH, Selvita S.A, Neurokine Pharmaceuticals Inc., VivaCell Biotechnology Espana S.L., Mnemosyne Pharmaceuticals, Inc., Revalesio Corporation, Genervon Biopharmaceuticals, LLC, centrose llc, Delenex Therapeutics AG, Chase Pharmaceuticals Corporation, Kareus Therapeutics, SA, Icure Pharmaceutical Inc., NeuroPhage Pharmaceuticals, Inc., AlzProtect SAS, Echo Pharmaceuticals B.V., SOM Biotech SL, Bionure, P2D Bioscience, International Biotechnology Center Generium, Valens Therapeutics, Inc., EncephRx, Inc., High Point Pharmaceuticals, LLC, Arrien Pharmaceuticals, LLC, Allinky Biopharma, CalAsia Pharmaceuticals, Inc., SK Biopharmaceuticals Co., Ltd., Io Therapeutics, Inc., PeptiDream Inc., Merz Pharmaceuticals GmbH, NeuroGenetic Pharmaceuticals, Inc., RAPID Pharmaceuticals AG, Tetra Discovery Partners LLC, Istituto Italiano di Tecnologia, Neurodyn Inc., GliaCure Inc., AbbVie Inc., Angita B.V., Alzinova AB, Inventiva SAS, Cellular Biomedicine Group, Inc., Northern Light Pharmaceuticals AB, Avergen Ltd, AlzeCure Discovery AB, Apodemus AB, Bionature E.A. Ltd.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Parkinson's Disease - Pipeline Review, H1 2014
- Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2014
- Crohn's Disease - Pipeline Review, H1 2014
- Huntington's Disease - Pipeline Review, H1 2014
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014
- Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2014
- Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2014
- Batten Disease - Pipeline Review, H1 2014
- Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Pipeline Review, H1 2014
Media Relations Contact
Director of Marketing
Fast Market Research, Inc.
View this press release online at: http://rwire.com/492481